Triatomic Management LP Adaptive Biotechnologies Corp Transaction History

Triatomic Management LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$2.88 - $4.8 $28,800 - $48,000	-10,000 Reduced 9.21%	98,555 $316,000
Q4 2023 Feb 13, 2024	BUY	$3.46 - $5.33 $19,604 - $30,199	5,666 Added 5.51%	108,555 $531,000
Q3 2023 Nov 03, 2023	SELL	$5.07 - $8.44 $92,664 - $154,257	-18,277 Reduced 15.08%	102,889 $560,000
Q2 2023 Aug 14, 2023	BUY	$6.19 - $8.78 $276,111 - $391,640	44,606 Added 58.26%	121,166 $813,000
Q1 2023 May 03, 2023	SELL	$7.8 - $10.11 $423,111 - $548,416	-54,245 Reduced 41.47%	76,560 $676,000
Q4 2022 Feb 13, 2023	SELL	$6.26 - $9.34 $1.1 Million - $1.63 Million	-175,000 Reduced 57.23%	130,805 $999,000
Q3 2022 Nov 14, 2022	SELL	$6.5 - $12.67 $157,144 - $306,309	-24,176 Reduced 7.33%	305,805 $2.18 Million
Q2 2022 Aug 12, 2022	BUY	$6.4 - $14.73 $210,771 - $485,103	32,933 Added 11.09%	329,981 $2.67 Million
Q1 2022 May 12, 2022	BUY	$10.12 - $28.9 $2.31 Million - $6.59 Million	228,108 Added 330.88%	297,048 $4.12 Million
Q4 2021 Feb 14, 2022	BUY	$25.17 - $36.85 $1.74 Million - $2.54 Million	68,940 New	68,940 $1.93 Million

202

146M

68.8K

42.5K

Ticker ADPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 142,872,992
Market Cap $812M
Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...

Get notified when there are updates to the investment portfolio of Triatomic Management LP, based on Form 13F filings with the SEC.

Stay updated on Triatomic Management LP with notifications on news.